Atrys Health (XMAD:ATRY) EBITDA per Share: €-0.12 (TTM As of Dec. 2025)


XMAD:ATRY Atrys Health SA XMAD:ATRY
66 GF Score
Price €2.54
GF Value €3.12
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health EBITDA per Share?

Atrys Health XMAD:ATRY -0.59% 66 EBITDA per Share is €-0.12 as of Dec. 2025. GuruFocus rates XMAD:ATRY with a GF Score™ of 66/100 and a GF Value™ of €3.12 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,141 Biotechnology companies, Atrys Health ranks worse than 87642.33% on this metric.

Atrys Health's EBITDA per Share for the six months ended in Dec. 2025 was €-0.32. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.12.

During the past 12 months, the average EBITDA per Share Growth Rate of Atrys Health was -158.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Atrys Health's EBITDA per Share or its related term are showing as below:

During the past 10 years, the highest 3-Year average EBITDA per Share Growth Rate of Atrys Health was 58.20% per year. The lowest was -14.70% per year. And the median was 10.50% per year.

XMAD:ATRY's 3-Year EBITDA Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Atrys Health's EBITDA for the six months ended in Dec. 2025 was €-24.1 Mil.

During the past 12 months, the average EBITDA Growth Rate of Atrys Health was -158.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 10 years, the highest 3-Year average EBITDA Growth Rate of Atrys Health was 114.60% per year. The lowest was 20.90% per year. And the median was 43.75% per year.


Atrys Health  (XMAD:ATRY) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Atrys Health EBITDA per Share Related Terms


Atrys Health EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Atrys Health's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health EBITDA per Share Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.20 0.38 0.22 -0.13

Atrys Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.11 0.09 0.20 -0.32
XMAD:ATRY
66GF Score
Atrys Health SA XMAD:ATRY
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrys Health EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Atrys Health's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-9.964/75.899
=-0.13

Atrys Health's EBITDA per Share for the quarter that ended in Dec. 2025 is calculated as

EBITDA per Share(Q: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-24.116/75.838
=-0.32

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of €-0.12 mean?
Atrys Health (XMAD:ATRY) has a EBITDA per Share of €-0.12 as of Dec. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Atrys Health and its competitors. According to the industry distribution chart, Atrys Health ranks #999999 out of 1141 companies in the Biotechnology industry.
Is Atrys Health's EBITDA per Share too high?
Atrys Health's current EBITDA per Share is €-0.12. Based on the distribution chart, Atrys Health ranks #999999 out of 1141 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's EBITDA per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #999999 out of 1141 companies for EBITDA per Share. This places Atrys Health in the lower half of its industry. The industry median EBITDA per Share is 15.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Biotechnology company?
The median EBITDA per Share among Biotechnology companies is 15.00, based on 1,141 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Atrys Health and its competitors. For the Biotechnology industry, the median EBITDA per Share is 15.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrys Health's current EBITDA per Share is €-0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.12, compared to a current price of €2.54 — trading 18.8% below its estimated fair value. The current EBITDA per Share is €-0.12. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current EBITDA per Share is €-0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.54 is trading 18.8% below its estimated GF Value™ of €3.12. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • EBITDA per Share: €-0.12
  • GF Value™: €3.12 vs. price of €2.54 (18.8% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score

Get the complete analysis for XMAD:ATRY

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.54
Price
€3.12
GF Value